Close Menu

Breast Cancer

News and reporting on breast cancer.

The immunoassay can be used to monitor cancer cell remnants in a patient's body and help determine which patients need less invasive treatment.

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The firm said its test can be used to evaluate blood samples from people who present with suspicious growths in the breast, lung, prostate, colon, or brain.

The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.

PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.

The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.

The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.

The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.

The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.

Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.

Pages